ValuEngine downgraded shares of Insulet (NASDAQ:PODD) from a strong-buy rating to a buy rating in a report released on Monday.
Several other equities research analysts have also commented on PODD. Leerink Swann restated an outperform rating and set a $100.00 target price (down from $110.00) on shares of Insulet in a research report on Thursday, January 3rd. Oppenheimer set a $100.00 target price on shares of Insulet and gave the stock a hold rating in a research report on Friday, November 2nd. BidaskClub lowered shares of Insulet from a strong-buy rating to a buy rating in a research report on Tuesday, September 25th. UBS Group assumed coverage on shares of Insulet in a research report on Tuesday, November 27th. They set a buy rating and a $105.00 target price on the stock. Finally, Morgan Stanley decreased their target price on shares of Insulet from $105.00 to $90.00 and set an equal weight rating on the stock in a research report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $99.87.
PODD traded down $1.25 during trading on Monday, hitting $73.63. The stock had a trading volume of 7,893 shares, compared to its average volume of 1,112,644. The company has a debt-to-equity ratio of 2.95, a quick ratio of 3.99 and a current ratio of 4.58. The stock has a market capitalization of $4.56 billion, a P/E ratio of -159.76 and a beta of 1.56. Insulet has a twelve month low of $70.80 and a twelve month high of $108.90.
Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 1st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.01. The company had revenue of $151.10 million for the quarter, compared to analysts’ expectations of $148.82 million. Insulet had a negative net margin of 2.54% and a negative return on equity of 7.63%. Insulet’s revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.04) EPS. Sell-side analysts predict that Insulet will post -0.05 EPS for the current year.
In related news, SVP David Colleran sold 6,113 shares of the business’s stock in a transaction dated Wednesday, November 14th. The shares were sold at an average price of $80.41, for a total value of $491,546.33. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Aiman Abdel-Malek sold 602 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $88.58, for a total transaction of $53,325.16. The disclosure for this sale can be found here. Insiders sold a total of 8,451 shares of company stock worth $691,834 over the last quarter. Insiders own 3.60% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in Insulet by 0.4% in the 3rd quarter. FMR LLC now owns 8,778,854 shares of the medical instruments supplier’s stock valued at $930,119,000 after purchasing an additional 37,973 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Insulet by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 5,053,657 shares of the medical instruments supplier’s stock valued at $535,434,000 after purchasing an additional 84,209 shares in the last quarter. Vanguard Group Inc lifted its holdings in Insulet by 1.7% in the 3rd quarter. Vanguard Group Inc now owns 5,053,657 shares of the medical instruments supplier’s stock valued at $535,434,000 after purchasing an additional 84,209 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in Insulet by 57.4% in the 3rd quarter. William Blair Investment Management LLC now owns 1,871,961 shares of the medical instruments supplier’s stock valued at $198,334,000 after purchasing an additional 682,393 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in Insulet by 5.6% in the 3rd quarter. Clearbridge Investments LLC now owns 1,823,750 shares of the medical instruments supplier’s stock valued at $193,226,000 after purchasing an additional 96,266 shares in the last quarter.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Read More: What is the NASDAQ?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.